Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Transdermal granisetron has been shown to as effective as oral/ intravenous granisetron when
administered with or without dexamethasone. However, it has not been evaluated specifically
against the delayed response of chemotherapy-induced nausea and vomiting (CINV) in comparison
with palonosetron, as the complete response for the delayed phase was not reported in the
comparative study by Seol et al (Support Care Cancer 2016;24:945-952). Thus, transdermal
granisetron needs to be compared with palonosetron as part of dual and triple therapy in the
delayed phase of CINV.
This investigator-initiated study aims to compare the efficacy of granisetron transdermal
patch and palonosetron combined with NK-1 receptor antagonist and dexamethasone in the
prevention of delayed CINV in Chinese breast cancer patients who received high emetic or
moderate emetic chemotherapy.